Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

AACR 2017

1 - 5 Apr 2017
Walter E. Washington Convention Center, Washington, D.C., United States of America
Global horizons of the WIN consortium
Dr Vladimir Lazar - Chief Operating Officer, WIN Consortium
Global horizons of the WIN consortium ( Dr Vladimir Lazar - Chief Operating Officer, WIN Consortium )
27 Apr 2017
What is the WIN Consortium?
Dr John Mendelsohn - Chairman of the WIN Consortium
What is the WIN Consortium? ( Dr John Mendelsohn - Chairman of the WIN Consortium )
27 Apr 2017
Pembrolizumab and indoximod for melanoma
Prof Yousef Nabih Zakharia - Holden Comprehensive Cancer Center, University of I...
Pembrolizumab and indoximod for melanoma ( Prof Yousef Nabih Zakharia - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA )
13 Apr 2017
Projections of cancer incidence and burden among the HIV-positive population in ...
Jessica Yasmine Islam - University of North Carolina, Chapel Hill, USA
Projections of cancer incidence and burden among the HIV-positive population in the United States through 2030 ( Jessica Yasmine Islam - University of North Carolina, Chapel Hill, USA )
12 Apr 2017
Nivolumab for NSCLC: five years on
Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Nivolumab for NSCLC: five years on ( Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
12 Apr 2017
Avelumab for metastatic Merkel cell carcinoma after chemotherapy
Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Avelumab for metastatic Merkel cell carcinoma after chemotherapy ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Apr 2017
Nivolumab and ipilimumab combination for advanced skin cancer
Dr James Larkin - The Royal Marsden, London, UK
Nivolumab and ipilimumab combination for advanced skin cancer ( Dr James Larkin - The Royal Marsden, London, UK )
12 Apr 2017
Long-term clinical outcomes and analyses of atezolizumab for mTNBC
Prof Peter Schmid - Barts Cancer Institute, London, UK
Long-term clinical outcomes and analyses of atezolizumab for mTNBC ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
12 Apr 2017
Checkmate 067 - combined nivolumab and ipilimumab
Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Checkmate 067 - combined nivolumab and ipilimumab ( Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
12 Apr 2017
Glycemia positively associated with prostate cancer mortality in non-diabetic me...
Michael Marrone - Johns Hopkins University, Baltimore, USA
Glycemia positively associated with prostate cancer mortality in non-diabetic men ( Michael Marrone - Johns Hopkins University, Baltimore, USA )
12 Apr 2017
Durable responses to avelumab in patients with Merkel cell carcinoma
Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Durable responses to avelumab in patients with Merkel cell carcinoma ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Apr 2017
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors
Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors ( Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA )
12 Apr 2017
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analy...
Prof Peter Schmid - Barts Cancer Institute, London, UK
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
11 Apr 2017
Five-year follow-up of nivolumab in NSCLC
Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Five-year follow-up of nivolumab in NSCLC ( Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
11 Apr 2017
Mutations in cancer predisposition genes and risk for subsequent neoplasms
Dr Leslie Robison - St. Jude Children's Research Hospital, Memphis, USA
Mutations in cancer predisposition genes and risk for subsequent neoplasms ( Dr Leslie Robison - St. Jude Children's Research Hospital, Memphis, USA )
11 Apr 2017
Final overall survival analysis of MONARCH 1
Dr Hope Rugo - UCSF Medical Center, San Francisco, USA
Final overall survival analysis of MONARCH 1 ( Dr Hope Rugo - UCSF Medical Center, San Francisco, USA )
11 Apr 2017
Redefining tamoxifen for breast cancer
Gokul Das - Roswell Park Cancer Institute, Buffalo, USA
Redefining tamoxifen for breast cancer ( Gokul Das - Roswell Park Cancer Institute, Buffalo, USA )
11 Apr 2017
Olaparib and temozolomide for relapsed small cell lung cancer
Dr Anna Farago - Massachusetts General Hospital, Boston, USA
Olaparib and temozolomide for relapsed small cell lung cancer ( Dr Anna Farago - Massachusetts General Hospital, Boston, USA )
10 Apr 2017
Final results of the HERACLES trial in HER2-amplified colorectal cancer
Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy
Final results of the HERACLES trial in HER2-amplified colorectal cancer ( Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy )
10 Apr 2017
Treatment choices for HER2 amplified colorectal cancer
Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy
Treatment choices for HER2 amplified colorectal cancer ( Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy )
10 Apr 2017
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumou...
Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017
Neratinib in HER2 or HER3 mutant solid tumours
Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Neratinib in HER2 or HER3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017
Understanding response and resistance to cancer therapy: Lessons learned from me...
Dr Jennifer Wargo - The University of Texas MD Anderson Cancer Center, Houston, ...
Understanding response and resistance to cancer therapy: Lessons learned from melanoma ( Dr Jennifer Wargo - The University of Texas MD Anderson Cancer Center, Houston, USA )
10 Apr 2017
Tumour-treating fields complement chemotherapy in aggressive brain tumours
Prof Roger Stupp - Northwestern University, Chicago, USA
Tumour-treating fields complement chemotherapy in aggressive brain tumours ( Prof Roger Stupp - Northwestern University, Chicago, USA )
10 Apr 2017
Tumour treating fields added to standard chemotherapy in newly diagnosed gliobla...
Prof Roger Stupp - Northwestern University, Chicago, USA
Tumour treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): ( Prof Roger Stupp - Northwestern University, Chicago, USA )
10 Apr 2017